Dashboard
Manage Tickers

ATOSATOSSA THERAPEUTICS, INC.

Nasdaq atossatherapeutics.com


$ 1.36 $ -0.19 (-12.34 %)    

Wednesday, 17-Apr-2024 15:59:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 426.06 $ -5.26 (-1.22 %)
DIA $ 377.52 $ -0.53 (-0.14 %)
SPY $ 500.59 $ -2.98 (-0.59 %)
TLT $ 89.29 $ 0.98 (1.11 %)
GLD $ 219.60 $ -1.63 (-0.74 %)
$ 1.35
$ 1.59
$ 0.00 x 0
$ 0.00 x 0
$ 1.35 - $ 1.60
$ 0.59 - $ 2.31
4,058,404
na
170.21M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-22-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-13-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-13-2019 03-31-2019 10-Q
21 03-28-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-13-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 03-08-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-11-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-12-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-06-2015 06-30-2015 10-Q
36 05-13-2015 03-31-2015 10-Q
37 03-30-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-14-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
04/16/2024 15:01:19

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $4 price ...

atossa-therapeutics-and-quantum-leap-healthcare-initiates-i-spy-2-clinical-trial-to-evaluate-z-endoxifen-in-combination-with-abemaciclib-in-women-with-erher2--breast-cancer
Atossa Therapeutics And Quantum Leap Healt...
04/15/2024 12:39:34

The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Gr...

atossa-therapeutics-presents-data-from-40mg-cohort-of-phase-2-evangeline-clinical-trial
Atossa Therapeutics Presents Data From 40m...
04/09/2024 16:00:06

The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen...

hc-wainwright--co-maintains-buy-on-atossa-therapeutics-maintains-4-price-target
HC Wainwright & Co. Maintains Buy on Atoss...
04/02/2024 12:36:55

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $4 price t...

atossa-therapeutics-provides-five-year-z-endoxifen-treatment-update-on-fda-approved-expanded-access-program-for-a-us-breast-cancer-patient-says-patient-remains-cancer-free-and-has-reported-no-significant-safety-or-tolerability-issues-over-course-of-treatment
Atossa Therapeutics Provides Five-Year (Z)...
03/19/2024 12:32:31

atossa-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirements
Atossa Therapeutics Regains Compliance Wit...
03/18/2024 12:31:45

data-from-atossas-phase-2-evangeline-clinical-trial-to-be-presented-at-american-association-for-cancer-research-annual-meeting
Data From Atossa's Phase 2 EVANGELINE Clin...
03/06/2024 13:31:01

atossa-therapeutics-announces-first-patient-dosing-of-z-endoxifen-in-ongoing-recast-dcis-study
Atossa Therapeutics Announces First Patien...
02/22/2024 13:35:05

hc-wainwright--co-initiates-coverage-on-atossa-therapeutics-with-buy-rating-announces-price-target-of-4
HC Wainwright & Co. Initiates Coverage On ...
02/12/2024 12:39:46

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and a...

atossa-therapeutics-fully-enrolls-z-endoxifen-arm-of-i-spy-2-clinical-trial
Atossa Therapeutics Fully Enrolls (Z)-Endo...
02/07/2024 13:32:14

atossa-therapeutics-issues-letter-to-shareholders-from-steven-quay-md-phd-the-companys-president-and-chief-executive-officer
Atossa Therapeutics Issues Letter To Share...
01/09/2024 13:46:39

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...

atossa-therapeutics-announces-full-enrollment-of-phase-2-karisma-endoxifen-clinical-trial
Atossa Therapeutics Announces Full Enrollm...
11/20/2023 13:31:16

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...

atossa-therapeutics-q3-eps-005-beats-007-estimate
Atossa Therapeutics Q3 EPS $(0.05) Beats $...
11/13/2023 14:04:46

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-announces-greg-weaver-provided-notice-of-his-resignation-as-the-executive-vice-president-and-cfo-effective-oct-5
Atossa Therapeutics Announces Greg Weaver ...
10/06/2023 20:07:23

-SEC Filing

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
09/08/2023 21:31:44

breast-cancer-focused-atossa-therapeutics-can-possibly-change-treatment-paradigm-analyst
Breast Cancer-Focused Atossa Therapeutics ...
09/08/2023 18:47:56

Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and 

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
09/08/2023 17:31:11

benzingas-top-ratings-upgrades-downgrades-for-september-8-2023
Benzinga's Top Ratings Upgrades, Downgrade...
09/08/2023 15:00:31

cantor-fitzgerald-initiates-coverage-on-atossa-therapeutics-with-overweight-rating-announces-price-target-of-5
Cantor Fitzgerald Initiates Coverage On At...
09/08/2023 12:16:05

Cantor Fitzgerald analyst Louise Chen initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Overweight rating and a...

atossa-therapeutics-filed-a-petition-for-post-grant-review-with-the-us-patent-and-trademark-office-relating-to-one-of-the-companys-issued-patents-related-to-methods-for-making-and-using-endoxifen
Atossa Therapeutics Filed A Petition For P...
08/31/2023 10:56:43

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)